Addressing Missing Data in Clinical Trials

被引:81
作者
Fleming, Thomas R. [1 ]
机构
[1] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
POSTTRAUMATIC-STRESS-DISORDER; TO-CHILD TRANSMISSION; FOLLOW-UP; THERAPY; INTRAPARTUM; PREVENTION; ZIDOVUDINE; PATIENT; KAMPALA; UGANDA;
D O I
10.7326/0003-4819-154-2-201101180-00010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The reliability and interpretability of results from clinical trials can be substantially reduced by missing data. Frequently used approaches to address these concerns, such as upward adjustments in sample sizes or simplistic methods for handling missing data, including last-observation-carried-forward, complete-case, or worst-case analyses, are usually inadequate. Although rational imputation methods may be useful to treat missingness after it has occurred, these methods depend on untestable assumptions. Thus, the preferred and often only satisfactory approach to addressing missing data is to prevent it. Procedures should be in place to maximize the likelihood that outcome data will be obtained at scheduled times of evaluation for all surviving patients who have not withdrawn consent. To meaningfully reduce missing data, it is important to recognize and address many factors that commonly lead to higher levels of missingness. Ann Intern Med. 2011;154:113-117.
引用
收藏
页码:113 / +
页数:6
相关论文
共 20 条
[1]  
[Anonymous], 2013, Clinical trials: a practical approach
[2]  
[Anonymous], 14 INT AIDS C BARC S
[3]  
[Anonymous], 1986, Ethics and regulation of clinical research
[4]   A method to reduce loss to follow-up in clinical trials: informed, withdrawal of consent [J].
Cleland, JGE ;
Torp-Pedersen, C ;
Coletta, AP ;
Lammiman, MJ .
EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (01) :1-2
[5]  
Faden RR., 1986, A history and theory of informed consent
[6]   Identifying and addressing safety signals in clinical trials [J].
Fleming, Thomas R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (13) :1400-1402
[7]   Issues in Using Progression-Free Survival When Evaluating Oncology Products [J].
Fleming, Thomas R. ;
Rothmann, Mark D. ;
Lu, Hong Laura .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (17) :2874-2880
[8]   Sildenafil citrate therapy for pulmonary arterial hypertension [J].
Galiè, N ;
Ghofrani, HA ;
Torbicki, A ;
Barst, RJ ;
Rubin, LJ ;
Badesch, D ;
Fleming, T ;
Parpia, T ;
Burgess, G ;
Branzi, A ;
Grimminger, F ;
Kurzyna, M ;
Simonneau, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2148-2157
[9]  
Gordon Elisa J, 2006, Account Res, V13, P285, DOI 10.1080/08989620600848645
[10]   Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVMET 012 randomised trial [J].
Guay, LA ;
Musoke, P ;
Fleming, T ;
Bagenda, D ;
Allen, M ;
Nakabiito, C ;
Sherman, J ;
Bakaki, P ;
Ducar, C ;
Deseyve, M ;
Emel, L ;
Mirochnick, M ;
Fowler, MG ;
Mofenson, L ;
Miotti, P ;
Dransfield, K ;
Bray, D ;
Mmiro, F ;
Jackson, JB .
LANCET, 1999, 354 (9181) :795-802